Patient
Patient Therapy
In recent years numerous life-saving treatment options have been developed for the therapy of breast cancer. Today there is a wide selection of treatments available to fight each individual breast cancer type. For a personalized treatment recommendation different approaches are selected and combined based on a sound diagnosis. Clinical parameters guide the oncologist in assessing the suitable intervention e.g.:
Subtype
Systemic Therapy
Benefits of MammaTyper®
Luminal A-like
Endocrine therapy
Based on accurate measurement MammaTyper® supports differentiation of low risk Luminal A-like from high risk Luminal B-like by precise and reproducible MKI67 determination
Luminal B-like (HER2 negative)
Endocrine therapy + Cytotoxics
Accurate determination of hormone receptor > endocrine responder or non –responder Precise differentiation of low risk Luminal A-like from high risk Luminal B-like by accurate and reproducible MKI67 determination by MammaTyper®
Luminal B-like (HER2 positive)
Endocrine therapy + Cytotoxics + Anti-HER2
Accurate determination of hormone receptor expression by MammaTyper® > endocrine responder or non –responder Accurate determination of ERBB2 expression by MammaTyper®
HER2 positive (non-luminal)
Anti-HER2
Accurate determination of ERBB2 expression by MammaTyper®
Triple negative (ductal)
Cytotoxics
Accurate determination of ERBB2, ESR1, PGR expression negativity by MammaTyper®